---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005623"
form_type: "8-K"
ticker: "RDGL"
cik: "0001449349"
company_name: "VIVOS INC"
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-26T23:58:17.579056+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients

## Summary
- First 5 patients showed safety; Y-90 remained at injection site with no adverse events.
- One patient (cancerous node near trachea) showed over 80% reduction in tumor size and metastatic activity.
- Lead investigator to request Ethics Committee approval to expand trial from 30 to 50 patients.
- New deep-injection CT-guided device targets deeper tumors (lung, pancreatic); initial trial by June 30, expanded by year-end.
- Data to be published and shared with FDA to support IDE submission for expanded U.S. indications.

## SEC filing metadata
- accession: 0001493152-25-005623
- form_type: 8-K
- ticker: RDGL
- cik: 0001449349
- company_name: VIVOS INC
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1449349/000149315225005623/0001493152-25-005623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1449349/000149315225005623/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005623
- JSON: https://secwatch.observer/filing/0001493152-25-005623.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.